13F Holdings
中文EN

NVS NOVARTIS AG IFRS

Pharmaceutical Preparations · NYSE · SEC CIK 1114448 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY8.4%
TTM net income YoY17.1%
TTM EPS YoY21.8%
Revenue 3-yr CAGR8.9%
Net income 3-yr CAGR26.2%

Margins

Gross margin78.8%
Operating margin32.4%
Net margin25.6%
FCF margin32.3%
EBITDA margin—

Returns

ROE31.0%
ROA13.1%
ROIC (approx.)44.8%
Asset turnover0.51x

Leverage & solvency

Liabilities / assets58.0%
Debt / equity0.00x
Current ratio1.12x
Interest coverage15.42x

Cash quality & payout

Operating cash flow / net income1.37x
Accruals ratio-4.8%
Payout ratio55.9%
Capex / revenue2.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$54.53B$50.32B$45.44B$42.21B$42.78B
Cost of revenue$13.70B$12.83B$12.47B$11.58B$11.73B
Gross profit$42.98B$38.90B$34.19B$31.88B$32.24B
R&D expense$11.20B$10.02B$11.37B$9.17B$8.64B
SG&A expense$13.25B$12.57B$12.52B$12.19B$12.83B
Operating income$17.64B$14.54B$9.77B$7.95B$10.06B
Interest expense$1.14B$1.01B$855.00M$800.00M$787.00M
Pretax income$16.35B$13.64B$9.12B$7.18B$24.53B
Income tax$2.38B$1.70B$551.00M$1.13B$1.62B
Net income$13.98B$11.94B$14.85B$6.96B$24.02B
EPS (basic)7.215.927.153.1910.71
EPS (diluted)7.155.877.103.1710.63
Weighted avg. shares (diluted)1.96B2.04B2.09B2.20B2.26B
Balance sheet
Cash & equivalents$11.44B$11.46B$13.39B$7.52B$12.41B
Short-term investments$98.00M$1.89B$569.00M$11.09B$12.96B
Receivables$8.94B$7.42B$7.11B$8.07B$8.01B
Inventory$6.27B$5.72B$5.91B$7.17B$6.67B
Current assets$30.46B$29.70B$30.48B$36.91B$45.72B
PP&E, netmay include right-of-use assets (IFRS)$10.78B$9.46B$9.51B$10.76B$11.54B
Goodwill$25.57B$24.76B$23.34B$29.30B$29.59B
Intangibles$29.41B$26.91B$26.88B$31.64B$34.18B
Total assets$110.95B$102.25B$99.94B$117.45B$131.79B
Current liabilities$27.28B$28.69B$26.39B$28.66B$30.21B
Short-term debt$682.00M$642.00M$624.00M$863.00M$899.00M
Total liabilities$64.40B$58.12B$53.20B$58.03B$63.97B
Shareholders' equity$46.13B$44.05B$46.67B$59.34B$67.66B
Shares outstanding1.91B1.98B2.04B2.12B2.23B
Cash flow statement
Operating cash flow$19.14B$17.62B$14.46B$14.24B$15.07B
Capital expenditure$1.55B$1.37B$1.06B$916.00M$1.07B
Free cash flow$17.60B$16.25B$13.40B$13.32B$14.01B
Investing cash flow-$4.88B-$7.51B$5.60B$1.47B$4.21B
Financing cash flow-$14.87B-$11.74B-$14.28B-$20.56B-$16.26B
Stock-based compensation$1.10B$1.04B$865.00M$791.00M$700.00M
Dividends paid$7.82B$7.62B$7.25B$7.51B$7.37B
Share buybacks$9.21B$8.33B$8.72B$10.65B$3.06B

Free plan shows the latest 5 periods; Pro shows all 10 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.